Bioretec Oy
OMXH:BRETEC
Operating Margin
Bioretec Oy
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
FI |
B
|
Bioretec Oy
OMXH:BRETEC
|
55m EUR |
-92%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
221.6B USD |
17%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.6B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
138.9B USD |
18%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
134.8B USD |
22%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
108.1B USD |
19%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
59.7B USD |
14%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
50.2B EUR |
13%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
41.1B USD |
27%
|
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
259.1B CNY |
36%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
33B USD |
29%
|
Bioretec Oy
Glance View
Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Bioretec Oy's most recent financial statements, the company has Operating Margin of -92.5%.